Aclaris Therapeutics, Inc. Company Profile

02:02 EDT 18th March 2018 | BioPortfolio

Aclaris Therapeutics, Inc., started by the founders of Vicept Therapeutics, is a privately held specialty pharmaceutical dermatology company focused on the development of novel dermatologic therapies. Visit for more information.

News Articles [776 Associated News Articles listed on BioPortfolio]

Aclaris' seborrheic keratoses drug approved by FDA

Aclaris Therapeutics' Eskata, or hydrogen peroxide, topical solution, 40% was granted approval by the FDA as a treatment for  -More- 

Wart Medication Meets Primary And Secondary Endpoints In Phase 2 Trial

NewsIf approved, the A-101 45% Topical Solution developed by Aclaris Therapeutics would be the first FDA approved treatment for common warts, which affect more than 22 million Americans.

Aclaris Therapeutics Receives FDA Approval for Eskata (hydrogen peroxide) Topical Solution, 40% (w/w) for the Treatment of Raised Seborrheic Keratoses

MALVERN, Pa., Dec. 15, 2017 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a dermatologist-led biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA...

Investor Network: Aclaris Therapeutics, Inc. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / March 12, 2018 / Aclaris Therapeutics, Inc. (NASDAQ: ACRS) will be discussing their earnings results in their Q4 Earnings Call to be held on March 12, 2018 at 8:00 AM Ea...

Aclaris's drug to treat common skin growth gets FDA nod

(Reuters) - The U.S. Food and Drug Administration approved Aclaris Therapeutics Inc's topical drug to treat a common kind of skin growth called seborrheic keratoses, the company said on Friday.

Aclaris gets FDA nod for Eskata drug to treat raised seborrheic keratoses

Aclaris Therapeutics has secured approval from the US Food and Drug Administration (FDA) for Eskata (hydrogen peroxide) topical solution, 40% (w/w) for the treatment of raised seborrheic keratoses or ...

Aclaris Therapeutics Reports Third Quarter 2017 Financial Results

Management to Host Conference Call at 8:00 AM ET today MALVERN, Pa., Nov. 07, 2017 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a dermatologist-led biopharmaceutical compan...

Aclaris Therapeutics Mourns the Passing of Board Member Richard A. Bierly

MALVERN, Pa., Nov. 09, 2017 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (Nasdaq:ACRS), a dermatologist-led, biopharmaceutical company focused on identifying, developing and commercializing inn...

PubMed Articles [404 Associated PubMed Articles listed on BioPortfolio]

Recent developments in intracellular protein delivery.

Protein therapeutics based on transcription factors, gene editing enzymes, signaling proteins and protein antigens, have the potential to provide cures for a wide number of untreatable diseases, but c...

Alternative therapeutics for self-limiting infections-An indirect approach to the antibiotic resistance challenge.

Alternative therapeutics for infectious diseases is a top priority, but what infections should be the primary targets? At present there is a focus on therapies for severe infections, for which effecti...

Eyes on New Product Development: Preclinical Research.

Introduction to Volume 2 of JOPT Special Issue.

Introduction to Volume 1 of JOPT Special Issue.

Clinical Trials [134 Associated Clinical Trials listed on BioPortfolio]

Impact of Ibis on Patients With Advanced COPD

The purpose of this research is to determine if Ibis™, a digital therapeutics solution developed by Senscio Systems, reduces the emergency room visits and hospitalizations of patients wi...

HDL Acute Lipid Optimization in Homozygous Familial Hypercholesterolemia

Assess the effect on coronary atheroma of serial infusions of autologous selectively delipidated HDL/preβ enriched plasma following use of HDL Therapeutics PDS-2™ System

Ontogenesis of the P-Glycoprotein in Human Lymphocytes Influence of HIV and Antiretroviral Therapeutics

The P-glycoprotein (P-gp) is a membranous transporter that modulates the intracellular concentrations of many drugs and plays thus a major role in the efficacy of the therapeutics that act...

A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas

The purpose of this first-in-human study of CX-072 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of CX-072 administered i...

A Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced Cancer

This is an open label, multi-center, Phase 1/2 study of BBI503 administered in combination with selected anti-cancer therapeutics in adult patients with advanced cancer. The goal of the st...

Companies [1199 Associated Companies listed on BioPortfolio]

Aclaris Therapeutics, Inc.

Aclaris Therapeutics, Inc., started by the founders of Vicept Therapeutics, is a privately held specialty pharmaceutical dermatology company focused on the development of novel de...

Aclaris Therapeutics Inc.

Aclaris Therapeutics, Inc., started by the founders of Vicept Therapeutics, is a privately held specialty pharmaceutical dermatology company focused on the development of novel de...

Aeris Therapeutics

Aeris Therapeutics is an emerging medical therapeutics company specializing in the development and commercialization of novel treatments for patients with emphysema and other adva...

Altair Therapeutics, Inc.

Based in San Diego, Altair Therapeutics, Inc. is a privately-held biopharmaceutical company developing novel therapeutics to treat human respiratory diseases. Altair Therap...

Vaxiion Therapeutics, Inc.

Vaxiion is dedicated to the design and development of intelligent drug-delivery technologies with special emphasis on targeted oncology therapeutics. Vaxiion Therapeutics was spun...

More Information about "Aclaris Therapeutics, Inc." on BioPortfolio

We have published hundreds of Aclaris Therapeutics, Inc. news stories on BioPortfolio along with dozens of Aclaris Therapeutics, Inc. Clinical Trials and PubMed Articles about Aclaris Therapeutics, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Aclaris Therapeutics, Inc. Companies in our database. You can also find out about relevant Aclaris Therapeutics, Inc. Drugs and Medications on this site too.

Quick Search


Corporate Database Quicklinks

Searches Linking to this Company Record